Suga S, Kimura K, Yokoyama Y
Gan To Kagaku Ryoho. 1983 Dec;10(12):2478-84.
Because of the great difficulty in detection of early lesion of Borrmann type 4 diffuse (scirrhous) gastric cancer, diagnosis is frequently given to the patients with far advanced, widely spread cancer invasion in the stomach which is not infrequently associated with peritonitis carcinomatosa. Accordingly, cancer chemotherapy should be of great importance. We have designed UFTM chemotherapy (a combination of UFT and Mitomycin C) for gastric cancer on the basis of pharmacodynamics of UFT. Twenty-one patients with Borrmann type 4 gastric cancer were treated with UFTM therapy. Of 21 patients, 14 (66.7%) patients experienced clinical responses. Fifty percent survival time after initiation of therapy was 11 months for the responders and 5.7 months for the non-responders. Overall fifty percent survival time was 8.4 months. It is considered that one of the keypoints of chemotherapy for Borrmann type 4 gastric cancer will be the complete treatment of metastatic lesion in the peritoneum which will become lethal to the patients later. Further, discussion was widely made on the treatment of Borrmann type 4 diffuse (scirrhous) gastric cancer.
由于Borrmann 4型弥漫性（硬癌）胃癌的早期病变极难检测，因此常常在患者胃癌已发展到晚期、广泛扩散且常伴有癌性腹膜炎时才得以诊断。因此，癌症化疗至关重要。我们基于优福定（UFT）的药效学设计了用于胃癌治疗的UFTM化疗方案（UFT与丝裂霉素C联合使用）。21例Borrmann 4型胃癌患者接受了UFTM治疗。21例患者中，14例（66.7%）出现临床反应。治疗开始后的50%生存时间，有反应者为11个月，无反应者为5.7个月。总体50%生存时间为8.4个月。可以认为，Borrmann 4型胃癌化疗的关键要点之一将是彻底治疗腹膜转移灶，否则这些转移灶随后将对患者构成致命威胁。此外，还就Borrmann 4型弥漫性（硬癌）胃癌的治疗展开了广泛讨论。
